| Year |
Citation |
Score |
| 2023 |
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, et al. A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532. PMID 37141550 DOI: 10.1200/PO.22.00532 |
0.349 |
|
| 2022 |
Micalizzi DS, Che D, Nicholson BT, Edd JF, Desai N, Lang ER, Toner M, Maheswaran S, Ting DT, Haber DA. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. Proceedings of the National Academy of Sciences of the United States of America. 119: e2209563119. PMID 36256815 DOI: 10.1073/pnas.2209563119 |
0.424 |
|
| 2022 |
Karabacak NM, Zheng Y, Dubash TD, Burr R, Micalizzi DS, Wittner BS, Lin M, Wiley DF, Comaills V, Emmons E, Niederhoffer KL, Ho U, Ukleja J, Che D, Stowe H, et al. Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition. Cancer Research. PMID 35045985 DOI: 10.1158/0008-5472.can-21-2609 |
0.364 |
|
| 2021 |
Micalizzi DS, Ebright RY, Haber DA, Maheswaran S. Translational Regulation of Cancer Metastasis. Cancer Research. PMID 33479028 DOI: 10.1158/0008-5472.CAN-20-2720 |
0.386 |
|
| 2020 |
Ebright RY, Zachariah MA, Micalizzi DS, Wittner BS, Niederhoffer KL, Nieman LT, Chirn B, Wiley DF, Wesley B, Shaw B, Nieblas-Bedolla E, Atlas L, Szabolcs A, Iafrate AJ, Toner M, et al. HIF1A signaling selectively supports proliferation of breast cancer in the brain. Nature Communications. 11: 6311. PMID 33298946 DOI: 10.1038/s41467-020-20144-w |
0.468 |
|
| 2020 |
Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, et al. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32571788 DOI: 10.1158/1078-0432.Ccr-20-0638 |
0.483 |
|
| 2020 |
Lee S, Micalizzi D, Truesdell SS, Bukhari SIA, Boukhali M, Lombardi-Story J, Kato Y, Choo MK, Dey-Guha I, Ji F, Nicholson BT, Myers DT, Lee D, Mazzola MA, Raheja R, et al. A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. Genome Biology. 21: 33. PMID 32039742 DOI: 10.1186/S13059-020-1936-4 |
0.347 |
|
| 2020 |
Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S, Mai A, Aceto N, Vincent-Jordan N, Szabolcs A, Chirn B, ... ... Micalizzi DS, et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science (New York, N.Y.). PMID 32029688 DOI: 10.1126/Science.Aay0939 |
0.576 |
|
| 2020 |
Wander SA, Juric D, Supko JG, Micalizzi DS, Spring L, Vidula N, Beeler M, Habin KR, Viscosi E, Fitzgerald DM, Scarpetti L, Tripp E, Hepp R, Moy B, Isakoff SJ, et al. Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC). Journal of Clinical Oncology. 38: 1066-1066. DOI: 10.1200/Jco.2020.38.15_Suppl.1066 |
0.317 |
|
| 2018 |
Micalizzi DS, Maheswaran S. On the trail of invasive cells in breast cancer. Nature. 554: 308-309. PMID 32094721 DOI: 10.1038/D41586-018-01634-W |
0.559 |
|
| 2018 |
Micalizzi DS, Maheswaran S. On the trail of invasive cells in breast cancer. Nature. 554: 308-309. PMID 29446387 DOI: 10.1038/d41586-018-01634-w |
0.522 |
|
| 2017 |
Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes & Development. 31: 1827-1840. PMID 29051388 DOI: 10.1101/Gad.305805.117 |
0.439 |
|
| 2017 |
Micalizzi DS, Haber DA, Maheswaran S. Cancer metastasis through the prism of epithelial to mesenchymal transition in circulating tumor cells. Molecular Oncology. PMID 28544498 DOI: 10.1002/1878-0261.12081 |
0.561 |
|
| 2015 |
Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, et al. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications. 6: 10077. PMID 26687066 DOI: 10.1038/Ncomms10077 |
0.64 |
|
| 2015 |
Micalizzi DS, Juric D, Niemierko A, Reynolds KL, Borger D, Vora SR, Isakoff SJ, Moy B, Ellisen LW, Bardia A. Abstract P1-13-03: Association of PIK3CA mutation with clinical response to specific endocrine therapies in metastatic hormone receptor positive (HR+) breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-13-03 |
0.479 |
|
| 2012 |
Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Research : Bcr. 14: R100. PMID 22765220 DOI: 10.1186/Bcr3219 |
0.769 |
|
| 2012 |
Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. The Journal of Clinical Investigation. 122: 1895-906. PMID 22466647 DOI: 10.1172/Jci59858 |
0.777 |
|
| 2012 |
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene. 31: 5162-71. PMID 22286770 DOI: 10.1038/Onc.2012.11 |
0.627 |
|
| 2012 |
Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene. 31: 552-62. PMID 21706047 DOI: 10.1038/Onc.2011.259 |
0.79 |
|
| 2012 |
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Ford HL. Abstract A20: The Six1-regulated miR-106b-25 cluster is a mediator of the tumor promotional effects of TGF- signaling in human breast cancer Cancer Research. 72: A20-A20. DOI: 10.1158/1538-7445.Nonrna12-A20 |
0.624 |
|
| 2011 |
Wang C, Jedlicka P, Christensen KL, Micalizzi DS, Harrell JC, Ford HL. Abstract 1463: SIX1 induces lymphatic and distant metastasis by upregulating VEGF-C and stimulating lymphangiogenesis in breast cancer Cancer Research. 71: 1463-1463. DOI: 10.1158/1538-7445.Am2011-1463 |
0.739 |
|
| 2010 |
Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Research. 70: 10371-80. PMID 21056993 DOI: 10.1158/0008-5472.Can-10-1354 |
0.748 |
|
| 2010 |
Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. Journal of Mammary Gland Biology and Neoplasia. 15: 117-34. PMID 20490631 DOI: 10.1007/S10911-010-9178-9 |
0.786 |
|
| 2009 |
Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncology (London, England). 5: 1129-43. PMID 19852726 DOI: 10.2217/Fon.09.94 |
0.715 |
|
| 2009 |
Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of Clinical Investigation. 119: 2678-90. PMID 19726885 DOI: 10.1172/Jci37815 |
0.752 |
|
| 2008 |
Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Research. 68: 2204-13. PMID 18381426 DOI: 10.1158/0008-5472.Can-07-3141 |
0.689 |
|
| Show low-probability matches. |